Free Trial
→ URGENT: If you own a home, please review the map below. (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$305.23
-0.1%		$326.76
$198.02
▼
$382.54
$9.06B0.56321,867 shs109,686 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
-0.15%+1.45%-7.70%-8.14%+50.34%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$305.23
-0.1%		$326.76
$198.02
▼
$382.54
$9.06B0.56321,867 shs109,686 shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
-0.15%+1.45%-7.70%-8.14%+50.34%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
2.93
Moderate Buy$375.0022.86% Upside

Current Analyst Ratings Breakdown

Latest KRYS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/4/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeBuy (B) ➝ Buy (B-)
11/3/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$416.00 ➝ $412.00
11/3/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetBuy$403.00 ➝ $380.00
11/3/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetOutperform$400.00 ➝ $375.00
10/23/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeBuy (B-) ➝ Buy (B)
10/23/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeHold ➝ Strong Sell
10/15/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy
10/15/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$361.00
10/9/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeBuy (B) ➝ Buy (B-)
9/24/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeBuy (B-) ➝ Buy (B)
(Data available from 11/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$389.13M23.24$7.28 per share41.93$48.44 per share6.30
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$204.83M$7.3741.4234.26N/A47.91%17.02%15.48%N/A

Latest KRYS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/2/2026Q3 2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$1.79$2.05+$0.26$2.05$125.77 million$127.34 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/A
7.89
7.53

Institutional Ownership

CompanyInstitutional Ownership
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
86.29%

Insider Ownership

CompanyInsider Ownership
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
13.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
29529.63 million25.75 millionOptionable

Recent News About These Companies

Krystal Biotech to Present at Upcoming Investor Conferences
November 10, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/krystal-biotech-to-present-at-upcoming-investor-conferences-1036742367
Krystal Biotech, Inc. 2026 Q3 - Results - Earnings Call Presentation
November 7, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4964762-krystal-biotech-inc-2026-q3-results-earnings-call-presentation
Krystal Biotech, Inc. (NASDAQ:KRYS) Stock Now Rated “Moderate Buy” by Wall Street Analysts
November 7, 2026  |  defenseworld.netD
Krystal Biotech, Inc. (KRYS) - What Are Researchers Saying About This Stock?
November 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31184020
Krystal Biotech, Inc. (NASDAQ:KRYS) Stock Now Rated "Moderate Buy" by Wall Street Analysts
November 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-krystal-biotech-inc-nasdaq-krys-stock-now-rated-moderate-buy-by-wall-street-analysts-2026-11-07/
HC Wainwright Comments on Krystal Biotech FY2026 Earnings
November 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31180844
Royal Bank Of Canada Issues Pessimistic Forecast for Krystal Biotech (NASDAQ:KRYS) Stock Price
November 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31179351
TD Cowen Has Lowered Expectations for Krystal Biotech (NASDAQ:KRYS) Stock Price
November 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31179346
Krystal Biotech (NASDAQ:KRYS) Stock Price Target Cut by Citigroup
November 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31179076
HC Wainwright Boosts Earnings Estimates for Krystal Biotech
November 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-hc-wainwright-boosts-earnings-estimates-for-krystal-biotech-2026-11-04/
Krystal Biotech, Inc. $KRYS Stock: Torray Investment Partners LLC Decreases Position
November 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-krystal-biotech-inc-krys-stock-torray-investment-partners-llc-decreases-position-2026-11-04/
Krystal Biotech Q3 Net Income Falls, Revenue Rises; Shares Up Pre-Bell
November 3, 2026  |  marketscreener.comM
Krystal Biotech (NASDAQ:KRYS) Given New $412.00 Price Target at Citigroup
November 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-krystal-biotech-nasdaq-krys-given-new-41200-price-target-at-citigroup-2026-11-03/
Krystal Biotech Offers Good Prospects Amid Pipeline Delays, RBC Says
November 3, 2026  |  marketscreener.comM
Krystal Biotech (NASDAQ:KRYS) Stock Gets Price Target Trim from TD Cowen
November 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-krystal-biotech-nasdaq-krys-stock-gets-price-target-trim-from-td-cowen-2026-11-03/
Krystal Biotech (NASDAQ:KRYS) Price Target Cut to $375.00 by Analysts at Royal Bank Of Canada
November 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-krystal-biotech-nasdaq-krys-price-target-cut-to-37500-by-analysts-at-royal-bank-of-canada-2026-11-03/
Earnings Beat May Change The Case For Krystal Biotech (KRYS) Stock
November 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/earnings-beat-may-change-case-051030816.html
Krystal Biotech (KRYS) Stock Stays Above Fair Value After Buyback Plan
November 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/krystal-biotech-krys-stock-stays-061122030.html
Krystal Biotech (NASDAQ:KRYS) Share Price Crosses Below Two Hundred Day Moving Average - Should You Sell?
November 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-krystal-biotech-nasdaq-krys-share-price-crosses-below-two-hundred-day-moving-average-should-you-sell-2026-11-03/
Is Krystal Biotech (KRYS) Undervalued On Earnings, Buybacks, And Vyjuvek Growth?
November 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/krystal-biotech-krys-undervalued-earnings-021632408.html
Krystal Biotech’s $400 Million Buyback: Short-Term Price Support vs. Long-Term Value and Funding Risks
November 3, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/krystal-biotechs-400-million-buyback-short-term-price-support-vs-long-term-value-and-funding-risks?utm_source=marketbeat.com&utm_medium=referral

New MarketBeat Followers Over Time

Media Sentiment Over Time

Krystal Biotech stock logo

Krystal Biotech NASDAQ:KRYS

$305.23 -0.45 (-0.15%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$307.50 +2.27 (+0.74%)
As of 11/13/2026 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas